PMID- 21726204
OWN - NLM
STAT- MEDLINE
DCOM- 20120109
LR  - 20201226
IS  - 1399-0039 (Electronic)
IS  - 0001-2815 (Linking)
VI  - 78
IP  - 2
DP  - 2011 Aug
TI  - KIR/HLA gene combinations influence susceptibility to B-cell chronic lymphocytic 
      leukemia and the clinical course of disease.
PG  - 129-38
LID - 10.1111/j.1399-0039.2011.01721.x [doi]
AB  - The aim of this study was to analyze the association between gene polymorphisms 
      of killer-cell immunoglobulin-like receptors (KIRs) and their human leukocyte 
      antigen (HLA) ligands and susceptibility to B-cell chronic lymphocytic leukemia 
      (B-CLL) and the clinical course of disease. The distribution of individual KIR 
      genes in 197 B-CLL patients and 200 controls was similar, except for a tendency 
      for lower frequencies of the KIR2DS3 and KIR2DL5 genes among B-CLL patients 
      (26.9% vs 35.5%, P = 0.06, 46.2% vs 55.5%, P = 0.06). The associations between 
      KIR2DS3 and B-CLL reached statistical significance in women (P = 0.05). Moreover, 
      we found a trend toward a lower frequency of genotypes with the presence of five 
      or six activating KIR genes in B-CLL patients compared to controls (20.8% vs 
      29.0%, P = 0.06), and a significantly higher frequency of individuals possessing 
      genotypes with a prevalence of inhibitory over activating KIR genes (ratio < 
      0.71) among B-CLL patients (P = 0.04). The HLA-Bw4 specificity was significantly 
      reduced among B-CLL patients (48.7% vs 63.0%, P = 0.005), which resulted from a 
      decreased frequency of HLA-Bw4(Thr80) (21.6% vs 32.0%, P = 0.02). Moreover, among 
      HLA-Bw4-positive individuals, progression-free survival (PFS) tended to be higher 
      in the presence of KIR3DS1 (77% +/- 9% vs 39% +/- 13%, P = 0.07). However, in B-CLL 
      patients, the presence of HLA-C2 was associated with decreased PFS (49% +/- 9% vs 
      75% +/- 7%, P = 0.02), and among HLA-C2-positive patients, the probability of PFS 
      was significantly reduced in the absence of KIR2DS1 (34% +/- 11% vs 77% +/- 7%, P = 
      0.007). Our results indicate that the pattern of inhibitory/activating KIR genes, 
      together with their HLA ligands, is associated with susceptibility to B-CLL and 
      affects the clinical course of this disease.
CI  - (c) 2011 John Wiley & Sons A/S.
FAU - Karabon, L
AU  - Karabon L
AD  - Department of Experimental Therapy, Institute of Immunology and Experimental 
      Therapy, Polish Academy of Sciences, Wroclaw, Poland. lkarabon@iitd.pan.wroc.pl
FAU - Jedynak, A
AU  - Jedynak A
FAU - Giebel, S
AU  - Giebel S
FAU - Wolowiec, D
AU  - Wolowiec D
FAU - Kielbinski, M
AU  - Kielbinski M
FAU - Woszczyk, D
AU  - Woszczyk D
FAU - Kapelko-Slowik, K
AU  - Kapelko-Slowik K
FAU - Kuliczkowski, K
AU  - Kuliczkowski K
FAU - Frydecka, I
AU  - Frydecka I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Tissue Antigens
JT  - Tissue antigens
JID - 0331072
RN  - 0 (HLA Antigens)
RN  - 0 (Ligands)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Case-Control Studies
MH  - Disease-Free Survival
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Genotype
MH  - HLA Antigens/*genetics
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/*immunology
MH  - Ligands
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Receptors, KIR/*genetics
EDAT- 2011/07/06 06:00
MHDA- 2012/01/10 06:00
CRDT- 2011/07/06 06:00
PHST- 2011/07/06 06:00 [entrez]
PHST- 2011/07/06 06:00 [pubmed]
PHST- 2012/01/10 06:00 [medline]
AID - 10.1111/j.1399-0039.2011.01721.x [doi]
PST - ppublish
SO  - Tissue Antigens. 2011 Aug;78(2):129-38. doi: 10.1111/j.1399-0039.2011.01721.x.